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Abstract. Item response theory (IRT) was used to characterize the time course of lower
urinary tract symptoms due to benign prostatic hyperplasia (BPH-LUTS) measured by item-
level International Prostate Symptom Scores (IPSS). The Fisher information content of IPSS
items was determined and the power to detect a drug effect using the IRT approach was
examined. Data from 403 patients with moderate-to-severe BPH-LUTS in a placebo-
controlled phase II trial studying the effect of degarelix over 6 months were used for
modeling. Three pharmacometric models were developed: a model for total IPSS, a
unidimensional IRT model, and a bidimensional IRT model, the latter separating voiding
and storage items. The population-level time course of BPH-LUTS in all models was
described by initial improvement followed by worsening. In the unidimensional IRT model,
the combined information content of IPSS voiding items represented 72% of the total
information content, indicating that the voiding subscore may be more sensitive to changes in
BPH-LUTS compared with the storage subscore. The pharmacometric models showed
considerably higher power to detect a drug effect compared with a cross-sectional and while-
on-treatment analysis of covariance, respectively. Compared with the sample size required to
detect a drug effect at 80% power with the total IPSS model, a reduction of 5.9% and 11.7%
was obtained with the unidimensional and bidimensional IPSS IRT model, respectively.
Pharmacometric IRT analysis of the IPSS within BPH-LUTS may increase the precision and
efficiency of treatment effect assessment, albeit to a more limited extent compared with
applications in other therapeutic areas.
KEY WORDS: item response theory; BPH; LUTS; International Prostate Symptom Score;
pharmacometrics.
INTRODUCTION
Benign prostate hyperplasia (BPH) is a common
condition in the aging male and is estimated to affect 50%
of males by age 60 years and 90% by age 85 years (1,2).
The clinical manifestations of BPH are known as lower
urinary tract symptoms (LUTS) and are characterized by an
increased: sensation of incomplete emptying of the bladder
following urination, urination frequency, urination intermit-
tency, urgency to urinate, weakness of the urinary stream,
straining to start urination, and nocturia. LUTS are associ-
ated with adverse health effects such as significantly
diminished quality of life and depression, as well as
impairment in activities of daily living (3–5). In approxi-
mately 10% of patients, the condition may lead to severe
complications such as acute urinary retention, urosepsis, and
kidney failure (2,6). The severity of BPH-LUTS is com-
monly measured by the International Prostate Symptom
Score (IPSS) (also known as the American Urological
Association score) (7), which consists of seven questions
describing the severity of each of the clinical manifestations
of LUTS. The IPSS questionnaire is considered the gold
standard measure for assessing BPH-LUTS, and its use is
widespread in the clinic, as a primary or secondary endpoint
in clinical trials, and in urology research (8).
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Pairwise cross-sectional testing based on the summary
score mean change from baseline is the traditional pre-
specified analysis for clinical trials using scale measures as the
primary efficacy endpoint. However, analysis of clinical trial
data through longitudinal pharmacometric modeling has been
shown to increase the power to detect a drug effect compared
with pairwise testing (9–11). Furthermore, an extension of
longitudinal pharmacometric modeling specific to multiple-
item questionnaire data (9), which utilizes concepts derived
from item response theory (IRT), has identified the potential for
increased assessment precision in several therapeutic areas
(namely, Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, and depression) (9,12–14). Moreover, the methodol-
ogy has shown an increase in the power to detect a drug effect
compared with longitudinal pharmacometric analysis of sum-
mary score data (9,15). Briefly, IRT quantifies the relationship
between an individual’s intrinsic trait (e.g., disability) and the
probability of answering a questionnaire (e.g., IPSS) in a
particular way (16,17). By preserving the information contained
within responses to individual items, it is possible to estimate an
individual’s latent disability, how well items discriminate be-
tween individuals with differing estimates of latent disability,
and the location of item responses along the disability scale.
The GnRH receptor antagonist, degarelix, approved for
the treatment of advanced prostate cancer (Firmagon®), was
investigated as an alternative medical approach for the treat-
ment of moderate-to-severe BPH-LUTS in patients without
prostate cancer. Due to its depot formation upon administration,
functioning as a slow-release formulation, treatment with
degarelix was envisioned to achieve greater compliance and
effectiveness compared with currently approved treatments
requiring daily administration. The degarelix doses tested within
BPH-LUTS were substantially lower than the approved doses
used for treating prostate cancer (a loading dose of 240 mg
followed by maintenance doses of 80 mg) to avoid eliciting
prolonged testosterone suppression in patients.
To date, only one publication describes longitudinal model–
based analysis of the total IPSS (18) and, moreover, longitudinal
pharmacometric IRTmodeling has not been applied to the analysis
of the IPSS within BPH-LUTS. Using data from 403 patients in a
phase II trial investigating the treatment of moderate-to-severe
BPH-LUTS with degarelix over 6 months, we set out to (i)
characterize the internal characteristics of the IPSS through IRT
analysis of the item-level data, (ii) utilize the obtained IRT
information to develop pharmacometric IRT models describing
the time course of underlying BPH-LUTS, and (iii) examine the
power to detect a drug effect of pharmacometric IRT IPSS
modeling compared with cross-sectional testing and longitudinal
modeling, respectively, based on total IPSS.
METHODS
Data
The IPSS is a seven-item questionnaire, where each item
can be scored from 0 to 5, yielding a composite IPSS ranging
from zero to 35. Item scores reflect symptom frequency (not
at all, less than 1 in five times, less than half the time, about
half the time, more than half the time, and almost always)
except for the nocturia item, where they correspond to
categorized counts (0 to ≥ 5 awakenings).
Ferring Pharmaceuticals’A/S trial CS36 (NCT00947882) was
a phase II, double-blind, parallel-group, dose-finding study evalu-
ating the efficacy and safety of degarelix over 6months. Following a
wash-out period, 403 patients were randomized to a single
subcutaneous injection of 10, 20, or 30 mg degarelix 40 mg/mL
solution, or placebo and were required to have an IPSS ≥ 13 at
screening 2 weeks prior to dosing at the baseline visit. The primary
endpoint was the mean change from baseline in IPSS compared
with placebo 3months after dosing. Visits were planned at 2 weeks,
and 1, 2, 3, 4, 5, and 6 months after dosing. Rich pharmacokinetic
sampling (n= 15) was performed in 43 patients while sparse (n= 2)
pharmacokinetic sampling was performed in 240 patients. An
interim trial analysis was planned for 6months post-dosing in order
to stop the trial early if the primary endpoint was not met. Trial
CS36 was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice.
Item Response Theory Modeling
The score for each of the seven IPSS items may range
from zero to five. The relationship between disability and the
probability (P) of a patient answering a score of at least k was
therefore modeled through a graded response model (19):
P Yij≥k
  ¼ ea j ψi−b j:kð Þ
1þ ea j ψi−b j:kð Þ
where Yij represents the score of patient i on item j, aj the
slope/discrimination parameter of item j, ψi the unobserved
disability of patient i, and bj the difficulty parameter of item j.
Cumulative probabilities for an item with a score of maximum
5 were modeled as follows:
P Yij ¼ 0
  ¼ 1−P Yij≥1 
P Yij ¼ k
  ¼ P Yij≥k −P Yij≥kþ 1 
P Yij ¼ 5
  ¼ P Yij≥5 
Item characteristic curves (ICCs) were estimated as fixed
effects by treating IPSS measurements from each patient’s
study visit as originating from a separate individual (in this
work referred to as the IDVIS approach). Disability was
estimated as a random effect, and its distribution was fixed to
a standard normal distribution (mean 0 and variance 1) at
baseline. Post-baseline shift parameters were included to
allow for a different mean and variance of disability post-
baseline (where disability is likely to have changed compared
with baseline due to placebo and/or drug effects). A similar
ICC estimation approach has been reported previously in the
literature (13,14,20,21).
Factor analysis (FA) is an established statistical method
(22) for assessing item patterns and informing the item
structure of IRT models (23). The procedure is aimed at
explaining the interrelationship between many observed
variables by way of few latent variables and is based on
analysis of the between-item correlation matrix. It may be
used to identify the number of questionnaire domains and
identify which items correspond to each of these (exploratory
FA) or to investigate the item patterns with a pre-specified
number of factors (confirmatory FA). Lastly, it may also
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inform whether the assumption of only one general dimen-
sion for all items is supported (24). In the current work, a
unidimensional IRT model was first fit to the CS36 data, and
the adequacy of the unidimensionality assumption was
assessed based on the item factor loadings. The latter indicate
an item’s correlation with the factor, where higher absolute
values suggest closer association. Following development of
the unidimensional IRT model, confirmatory FA with two
dimensions (a minimum of three items per dimension is
needed to preserve model identification) and varimax orthog-
onal rotation (25) was used to inform the item structure of a
bidimensional IRT model. In the developed IRT ICC models,
residual correlation between items was also assessed and was
calculated as follows:
RESij ¼ DVij−Eij
Eij ¼ P 1ð Þ∗1þ P 2ð Þ∗2þ P 3ð Þ∗3þ P 4ð Þ∗4þ P 5ð Þ∗5
with DVij being the observed score from the ith individual for
the jth IPSS item and Eij being the corresponding weighted
prediction based on the IRT-derived ICCs and individual
disability estimates.
Pharmacometric Implementation of Item Response Theory
Following the IRT ICC estimation step, the resulting
knowledge was incorporated into a pharmacometric framework.
First, the original individual assignment was reconciled with the
data (i.e., longitudinal observations were restored for each patient),
and IRT-derived latent disability estimates were modeled longitu-
dinally as the dependent variable. Uncertainty in the Empirical
Bayes Estimates (EBEs) of latent disability was taken into account
through an additional additive residual errormodel term, similar to
the IPPSE (individual PK parameters with standard errors)
approach in sequential PK/PD modeling (26) (we here name it
the PSI-IPPSE approach). Schindler et al. previously proposed a
similar approach (20) but without standard errors. Secondly and
lastly, the IRT ICC estimation model and the final longitudinal
latent disability model from the PSI-IPPSE step were combined
into a single model to allow translation of latent disability to
observed IPSS at the item and summary level, respectively. In the
latter model, the impact of re-estimating only the longitudinal
parameters, as well as the simultaneous estimation of ICCs and
longitudinal parameters, was examined.
Calculation of Fisher Information Content
To investigate which IPSS items carry the most informa-
tion (i.e., the signal-to-noise ratio in determining patients’
latent disability) and where on the disability scale they are
most informative, the Fisher information content of each
IPSS item was calculated as the negative expectation of the
second derivative of the log-likelihood using the unidimen-
sional IRT ICC estimation model. The information functions
were visualized to illustrate the sensitivity of each IPSS item
over the full disability range. Individual items were ranked
according to the amount of information they contained
relative to the total information based on each item’s
calculated area under the curve within this study’s estimated
disability range. Information content assessment was
performed in the context of unidimensional IRT modeling.
This allows for an overall perspective across all IPSS items
while in the multidimensional IRT framework, it is only
feasible within each separate dimension.
Structural Longitudinal Modeling
For underlying disability in the context of IRT as well
as observed total IPSS, a similar approach to longitudinal
model development was undertaken. First, data from
patients randomized to the placebo group were modeled.
Here, different structural models were tested to best
describe the time course of the placebo effect, such as
linear, bi-linear, power, exponential, Weibull, Gompertz,
and inverse Bateman models. The addition of a linear
drift parameter (27) to describe worsening or continued
improvement was tested for all abovementioned models.
Subsequently, data from patients assigned to degarelix
treatment were added to the data set to describe the drug
effect. In this step, we investigated models describing
degarelix treatment effects as present or absent, indepen-
dent of the administered dose, as well as dose-response
models (linear and Emax). An offset treatment effect, as
well as onset treatment effects to describe time delays in
reaching the full response (linear, exponential, slope-
intercept models), was investigated. Normally and log-
normally distributed between-subject variability was inves-
tigated for all parameters. For the total IPSS model,
additive, proportional, and combined error models were
investigated to describe residual variability.
Covariate Analysis
Investigated baseline covariates consisted of demo-
graphics (age, weight, and body mass index), physiological
disease-specific measures (total prostate volume, serum
testosterone, prostate-specific antigen, average flow rate,
flow time including time to maximum flow, maximum
urine flow, post-void residual volume, voiding time, and
voiding volume), validated disease-specific patient-re-
ported outcome (quality of life (QoL) score, BPH Impact
Index (BII) score), and study site region (North America
or Europe). Baseline IPSS was tested as a covariate on
the drug effect parameter during longitudinal IPSS model-
ing. Lastly, individual degarelix area under the curve
(AUC0-∞) estimates derived from application of a previ-
ously developed population pharmacokinetic model (28)
to the CS36 trial pharmacokinetic data were investigated
as a predictor of treatment effect variability, both as a
continuous value and binned by quartile.
Covariate analysis was performed by way of a
stepwise search at a significance level of 0.01 in the
forward inclusion step and 0.001 in the backward elimi-
nation step. Linear relationships were investigated for
covariates. A multiplicative covariate model (Eq. 1) was
used to test continuous covariates on parameters except in
the case of parameters liable to assume a typical value (θ)
of zero (e.g., baseline disability in longitudinal IRT
modeling), where an additive covariate model was used
(Eq. 2)
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Parameter ¼ θParameter
∗ 1þ θCovariate Covariate−Covariatemedianð Þð Þ
ð1Þ
Parameter ¼ θParameter
þ θCovariate Covariate−Covariatemedianð Þ ð2Þ
Model Evaluation and Diagnostics
Non-covariate–related model selection was based on
several criteria: for hierarchal models, the difference in
objective function value (OFV) corresponding to a signifi-
cance level of 0.05 was considered statistically significant
assuming a χ2 distribution while for non-nested models, the
difference in Akaike information criterion (AIC) was used.
Moreover, model stability based on the convergence of
minimization and covariance steps, parameter precision
assessed through NONMEM’s relative standard error esti-
mate, and graphical diagnostics were also considered during
model selection.
Visual predictive checks (VPCs) of the longitudinal IPSS, as
well as the change in IPSS frombaseline stratified by treatment arm
using 200 samples, were used to assess the adequacy of the model
characterization of the observed IPSS data.
In the IRT analyses, the goodness of fit of ICCs was assessed
using a novel sampling-based cross-validated generalized additive
model (GAM) cubic spline smooth, which builds upon the
commonly used GAM smooth diagnostic (21). As for all
pharmacometric model diagnostics, EBE-based visual representa-
tions may be misleading due to η-shrinkage (29). In this particular
diagnostic, EBE-shrinkage can cause an adequatemodel to appear
inadequate, in particular at extreme disability values. In order to
counteract the potential effects of η-shrinkage of disability EBEs
on the GAM smooth diagnostic, an approach was developed
utilizing random sampling from the individual posterior η distribu-
tions from the final ICC estimation model uncertainty estimate of
EBEs (Fisher information assessed variance or conditional vari-
ance). Two hundred η samples were drawn randomly, assuming
normal distributions with mean individual posterior η estimate and
variance individual η Fisher information assessed variance. Dis-
ability estimates were subsequently calculated for each generated η
while respecting the baseline or post-baseline IDVIS origin of η,
using the estimated fixed-effects post-baseline shift parameters.
Similar to the traditional IRT GAM diagnostic, GAM smooths
were applied to the data (one for each unique item–difficulty
category combination). To adjust for the difference between the
number of sampling-generated and number of actual study–
derived disability estimates, the 95% confidence interval of the
GAMsmoothswas adjusted bymultiplying the computed standard
error with the square root of the number of generated η samples.
To diagnose the final longitudinal IRT model, VPCs were
generated for both item-level IPSS observations and summary
IPSS scores using 2000 Monte Carlo simulations.
Power Calculations
A stochastic simulation and estimation (SSE) procedure with
1000 samples was used to assess the 80% power to detect a drug
effect at a 5% level of significance. Themodel with the lowest AIC
among the two developed longitudinal IRT models (unidimen-
sional and bidimensional) was chosen as the simulation model. For
simplicity, the Monte Carlo simulations assumed no missing
individual IPSS item scores and no drop-out over the 6-month
period. Power curves were generated by estimating the power of
the models at four different sample sizes, which were informed by
an initial exploratory Monte Carlo Mapped Power (MCMP) (30)
procedure. In the pharmacometric models, the actual type I error
level and corresponding empirically derived ΔOFV was estimated
by simulating 1000 trials with no drug effect at each sample size,
similar toWählby et al. (31). The power of two different analysis of
covariance (ANCOVA) tests was determined using the same
simulated data sets on which the power of the pharmacometric
models was estimated. Both analyses included treatment as factor
and baseline summary IPSS as a covariate. The first ANCOVA
used cross-sectional data, regarding only the change from baseline
at 3 months post-dose, which was the landmark time point in the
CS36 trial. This type of analysis is commonly pre-specified as the
main analysis of clinical trials. In the second ANCOVA, the
average summary IPSS change from baseline during the entire
treatment period was considered the dependent variable, which is
known as the “while on treatment” (WOT) strategy/estimand (32).
At each sample size, power was determined as the proportion of
analyses that identified a statistically significant (p< 0.05) treatment
effect.
Software
The Laplacian method in NONMEM version 7.4.3 (33)
was used for IRT ICC estimation and final longitudinal IRT
modeling, while the first-order conditional estimation with
interaction was used for longitudinal IPSS modeling as well as
intermediate longitudinal IRT modeling of EBEs of disability.
The mIRT R-package (34) version 1.32.0 was used to obtain
initial estimates for the ICCs and to perform factor analysis as
well as multidimensional IRT model exploration. ICC diag-
nostics were obtained using R version 4.6.0. Simulation-based
model diagnostics for the longitudinal models were obtained
using Perl-Speaks-NONMEM (35) (PsN) version 4.9.0.
RESULTS
Table I shows the subject characteristics at baseline. In total,
3117 summary IPSS and 21,836 item-level IPSS responses from 403
patients were available for analysis. The distribution of responses is
shown in Supplemental Fig. S1. Three hundred and sixty-nine of
the 403 randomized patients completed the 6-month treatment
period. Figure 1 shows the mean summary IPSS time course in
each trial arm as well as the distribution of responses for each IPSS
item. A marked drop in total IPSS was observed in all treatment
arms following dosing, and there was a similar distribution of item-
level IPSS responses at the three key trial visits (baseline, the
landmark time point, and end-of-trial) in both the placebo arm and
the pooled treatment arms. From Fig. 1, there was no apparent
dose-response for the effect of degarelix on the IPSS.
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Item Response Theory Analysis
The unidimensional IRT model had high (> 0.6) item
factor loadings except for the nocturia item, which had a
modest factor loading value of 0.39, suggesting adequacy of
the unidimensionality assumption. Factor analysis with two
dimensions identified items relating to voiding (the emptying,
intermittency, weak stream, and straining IPSS items) and
storage (the frequency, urgency, and nocturia IPSS items)
symptoms, respectively, as belonging to separate dimensions,
informing the development of a bidimensional IRT model
(item factor loading values are shown in Supplemental
Table S1).
Unidimensional Item Characteristic Curve Estimation Model
In the unidimensional IRT ICC estimation model, 44
parameters (35 difficulty parameters, 7 discrimination param-
eters, and 2 post-baseline shift disability parameters) were
estimated with low uncertainty in order to characterize the
ICCs (Table II). The incomplete emptying IPSS item had the
highest discrimination parameter value (1.38); i.e., it is more
sensitive to changes in disability around the difficulty
parameter of each score. The nocturia item had the lowest
discrimination parameter value (0.49), indicating that a large
increase in disability gives a relatively small increase in
probability of increased score. The ICCs of each IPSS item
are illustrated in Fig. 2 and show expected scores larger than
zero for individuals with low disability (< − 4) for all items,
most notably for the frequency, weak stream, and nocturia
items. For the nocturia item, individuals with a low disability
estimate are predominantly expected to score higher than 0,
indicating that the vast majority of patients will answer that
they get up to urinate at least once every night.
Both the traditional cross-validated cubic spline GAM
smooth and the sampling-based extension of the latter
indicated that the estimated ICCs described the data ade-
quately (Fig. 3). Better model agreement was observed with
the sampling-based GAM smooth compared with the tradi-
tional method, although low typical η-shrinkage (SD-based)
(9.6%) and low individual shrinkage variability (95% CI
9.6% to 9.9%, range 6.3% to 42.0%) was observed.
Total IPSS spanning the entirety of the scale were
observed in the CS36 data and high correlation (r2 = 0.95)
with estimated IRT disability was observed (Fig. 4a).
However, for a given summary IPSS value, there exists a
wide range of underlying disability, most evident for
moderate BPH-LUTS (8≤ IPSS ≤ 19). Moreover, Fig. 4b
illustrates that the minimal detectable decrease (MDD) of
three IPSS points (36,37) corresponds to a wide range of
decreases in latent disability. In turn, there is a notable
overlap between the latter disability improvements and those
corresponding to observed improvements below the MDD (−
3 <ΔIPSS < 0), no observed change (ΔIPSS = 0), and to a
small extent observed worsening (ΔIPSS > 0). Lastly, the
threshold commonly used to determine clinical progression
(ΔIPSS≥ 4) (37–40) corresponds to no change or increases in
underlying disability.
As shown in Table III, the most informative IPSS item
was incomplete emptying (23.8% of total information),
closely followed by intermittency (20.8% of total informa-
tion). These items can determine patients’ disability more
precisely relative to the other IPSS items. The nocturia item
was found to contain the least information (3.4%), which is in
line with this item having the lowest discrimination parameter
value (Table II). Of note, the IPSS voiding items (incomplete
emptying, intermittency, weak stream, and straining) com-
bined carried 72% of the total information while IPSS storage
items (frequency, urgency, and nocturia) combined only
Table I. Baseline Demographic and International Prostate Symptom Score (IPSS) Characteristics in Clinical Trial CS36
Variable Placebo Degarelix 10 mg Degarelix 20 mg Degarelix 30 mg
Number of patients 98 101 99 105
Age in years (median [range]) 65.0 [50.0, 86.0] 65.0 [50.0, 81.0] 66.0 [52.0, 82.0] 65.0 [50.0, 87.0]
Body weight in kg (median [range]) 86.4 [60.0, 128.0] 87.0 [54.1, 126.2] 85.0 [57.0, 141.2] 84.0 [55.0, 183.8]
Body mass index in kg/m/m (median [range]) 28.5 [20.1, 40.2] 27.8 [18.9, 40.5] 27.7 [21.4, 38.9] 27.7 [19.8, 58.1]
Total IPSS (median [range]) 18.0 [13.0, 33.0] 18.0 [11.0, 33.0] 19.0 [13.0, 33.0] 19.0 [13.0, 35.0]
IPSS storage subscore (median [range]) 8.0 [3.0, 15.0] 8.0 [3.0, 15.0] 8.0 [4.0, 15.0] 8.0 [2.0, 15.0]
IPSS voiding subscore (median [range]) 10.0 [4.0, 20.0] 11.0 [0.0, 20.0] 11.0 [3.0, 20.0] 11.0 [4.0, 20.0]
Quality of life score (median [range]) 4.0 [2.0, 6.0] 4.0 [1.0, 6.0] 4.0 [2.0, 6.0] 4.0 [3.0, 6.0]
BPH Impact Index score (median [range]) 7.0 [0.0, 13.0] 7.0 [0.0, 12.0] 7.0 [0.0, 12.0] 7.0 [0.0, 12.0]
Voided volume in mL (median [range]) 175.5 [77.0, 466.0] 188.1 [125.0, 632.0] 185.0 [57.0, 505.0] 186.0 [106.4, 484.0]
Voiding time in s (median [range]) 37.0 [19.0, 121.0] 40.0 [21.0, 128.0] 42.0 [15.0, 112.0] 39.0 [20.6, 344.5]
Post void residual volume in mL (median [range]) 39.1 [0.0, 230.0] 50.5 [0.0, 246.6] 45.0 [0.0, 189.0] 56.3 [0.0, 999.0]
Average flow rate in mL/s (median [range]) 5.0 [2.6, 10.4] 5.0 [2.6, 9.5] 5.3 [2.7, 10.6] 5.0 [2.3, 8.5]
Maximum urine flow in mL/s (median [range]) 10.0 [4.6, 16.4] 10.0 [4.4, 19.2] 10.0 [5.4, 50.0] 9.9 [5.1, 16.0]
Flow time including time to maximum flow
in s (median [range])
33.0 [18.0, 113.0] 36.0 [20.0, 120.0] 37.4 [13.0, 101.0] 37.0 [20.6, 100.4]
Total prostate volume in mL (median [range]) 39.1 [16.8, 102.0] 38.4 [14.2, 128.0] 38.3 [17.0, 155.7] 36.1 [9.8, 135.9]
Prostate specific antigen in ng/mL (median [range]) 2.0 [0.2, 9.6] 1.8 [0.1, 9.0] 2.3 [0.3, 9.6] 1.8 [0.3, 7.8]
Serum testosterone in ng/mL (median [range]) 4.1 [1.0, 10.2] 4.3 [0.2, 13.6] 4.3 [2.0, 8.0] 4.3 [0.6, 12.2]
Region North America (N, %) 57 (58.2) 60 (59.4) 60 (60.6) 63 (60.0)
Region Europe (N, %) 41 (41.8) 41 (40.6) 39 (39.4) 42 (40.0)
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contained 28% of the total information. A visual representa-
tion of the Fisher information curves for each item is shown in
Supplemental Fig. S2.
Bidimensional Item Characteristic Curve Estimation Model
In the bidimensional IRT ICC estimation model, 47
parameters were estimated with low uncertainty (35 difficulty
parameters, 7 discrimination parameters, two sets of post-
baseline shift disability parameters, and a correlation term
between latent variables) using Cholesky decomposition (to
estimate the correlation between the latent variables fixed to
1). The bidimensional ICC estimation model had a 407.5
lower OFV than the unidimensional ICC estimation model,
and its IRT parameter estimates and ICCs are presented in
Table II and visually represented in Supplemental Figs. S3
and S4, respectively. Estimated ICCs adequately described
the data as shown in Supplemental Figs. S5 and S6. Typical η-
shrinkage was 10% (individual shrinkage 95% CI 9.8% to
10%, range 6.9% to 38.6%) and 13% (individual shrinkage
95% CI 13.6% to 13.8%, range 9.8% to 38.8%) in the voiding
and storage dimension, respectively.
The residual correlation between items in the two
respective developed IRT ICC estimation models is shown
in Supplemental Figs. S7 and S8.
Longitudinal Models
Three longitudinal models were developed: a total score
model, a unidimensional IRT model, and a bidimensional
IRT model. All three developed models adequately described
the data as illustrated by VPCs (Supplemental Figs. S9, S10,
S11, S12, and S13).
The time course of IPSS and latent disability in the
summary score and unidimensional IRT model, respectively,
were described according to
IPSS or Disability ¼ Baselineþ PlaceboþDrug
where Baseline is the estimated baseline, Drug is the offset
degarelix treatment effect, and Placebo is the placebo effect
described by
Placebo ¼ Pmax 1−e− ln 2ð ÞTprog ∗Time
 
þDrift∗Time
where Pmax is the maximal placebo effect, Tprog is the half-
life to reach Pmax, and Drift describes worsening or
continued improvement.In the bidimensional IRT model,
the placebo effect in each dimension was described using a
Weibull function
Placebo ¼ Pmax 1−e− ln 2ð ÞTprog*Timeð Þ
WEI
 
þDrift∗Time
where WEI is the Weibull exponent. Separate offset drug
effects were estimated on each of the two latent variable
scales.
Fig. 1. The mean International Prostate Symptom Score (IPSS) in each CS36 trial arm along with the standard error of the
mean at each visit. The distribution of item-level IPSS at the baseline visit, landmark time point (3 months post-dose), and
end of trial (6 months post-dose) is shown for the placebo arm as well as the pooled degarelix dose arms
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Table II. Item Characteristic Curve (ICC) Parameter Estimates in the (a) Unidimensional and (b) Bidimensional Item Response Theory
(IRT) models
a b
Unidimensional model Bidimensional model
Parameter Estimate Relative standard error (%) Estimate Relative standard error (%)
IRT ICC parameters
a1 1.38 7.0 1.6 7.6
b1,1 − 4.09 5.9 − 3.4 7.2
b1,2 1.82 7.4 1.56 8.1
b1,3 1.68 6.7 1.44 7.4
b1,4 1.41 6.8 1.2 7.6
b1,5 1.27 8.0 1.09 8.5
a2 0.98 7.0 1.4 8.5
b2,1 − 5.39 6.0 − 4.83 7.4
b2,2 2.64 7.5 2.24 8.3
b2,3 2.04 6.7 1.8 7.8
b2,4 1.49 7.1 1.3 8.2
b2,5 1.55 7.8 1.3 8.2
a3 1.29 7.7 1.68 8.2
b3,1 − 3.77 6.0 − 3.03 7.4
b3,2 1.8 7.4 1.48 8.0
b3,3 1.6 7.1 1.32 7.7
b3,4 1.08 7.5 0.88 8.0
b3,5 1.34 8.1 1.1 8.4
a4 0.92 6.7 1.16 8.0
b4,1 − 3.86 5.6 − 3.65 7.3
b4,2 2.09 6.8 1.88 8.1
b4,3 1.68 6.6 1.55 7.7
b4,4 1.22 7.2 1.12 8.0
b4,5 1.42 7.7 1.27 8.7
a5 1.09 7.2 1.36 7.7
b5,1 − 5.11 6.3 − 4.16 7.3
b5,2 2.31 7.8 1.9 8.3
b5,3 1.69 7.0 1.4 7.7
b5,4 1.32 7.1 1.09 7.7
b5,5 1.12 7.5 0.93 8.1
a6 0.95 7.8 1.25 8.2
b6,1 − 3.1 6.1 − 2.46 7.5
b6,2 1.72 7.7 1.38 8.2
b6,3 1.68 7.5 1.35 8.1
b6,4 1.67 9.8 1.34 8.3
b6,5 1.67 8.4 1.34 10.1
a7 0.49 8.4 0.601 8.5
b7,1 − 7.89 7.5 − 6.93 7.7
b7,2 5.19 8.7 4.4 8.5
b7,3 3.52 8.1 3.04 8.2
b7,4 2.44 8.9 2.09 8.9
b7,5 2.1 10.5 1.77 10.2
Post-baseline shift parameters
Mean latent variable dimension 1 − 1.38 6.1 − 1.07 8.8
Variance latent variable dimension 1 2.22 6.4 1.61 7.3
Mean latent variable dimension 2 - - − 1.40 8.5
Variance latent variable dimension 2 – 2.4 7.4
Correlation between dimensions - - 69.1 3.6
ai is the discrimination parameter for item i; bi,k is the difficulty parameter for item i and category k. In the bidimensional model, dimension 1
(voiding) consists of items 1, 3, 5, and 6 while dimension 2 (storage) includes items 2, 4, and 7. At baseline, the latent variable(s) was fixed to
N(0, 1) while the mean and variance of the latent variable(s) was estimated for post-baseline data (IDVIS approach)
Item #1: “Incomplete Emptying”; Item #2: “Frequency”; Item #3: “Intermittency”; Item #4: “Urgency”; Item #5: “Weak Stream”, Item #6:
“Straining”, Item #7: “Nocturia”
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Final longitudinal model parameter estimates for the
total IPSS and unidimensional IRT model, along with their
precision, are shown in Table IV. The lowest OFV and best
goodness of fit were achieved by specifying log-normally
distributed inter-individual variability (IIV) for BaselineIPSS
and TprogIPSS and normally distributed IIV for PmaxIPSS, and
DriftIPSS. In longitudinal latent disability modeling, log-
normal IIV was specified for TprogDisability, while normal
distributions were specified for BaselineDisability, PmaxDisability,
and DriftDisability. The typical value of Drift was fixed to zero,
and no significant changes in OFV were observed by doing
so. The addition of IIV on Drug was not feasible in neither
longitudinal IPSS nor latent disability modeling, as it yielded
no significant OFV decrease and a variance close to zero,
indicating that placebo and drug effect variability could not
be distinguished in the current data. Incorporation of the
offset drug effect into the total IPSS model, unidimensional
IRT model, and bidimensional IRT model gave an OFV
reduction of 22.1 (df = 1), 20.3 (df = 1), and 42.5 (df = 2),
respectively, compared with the respective models without an
estimated drug effect. No dose-response or exposure-
response using AUC0-∞ as the exposure metric was observed
on the IPSS and latent disability scale, respectively.
In the longitudinal the total IPSS and unidimensional
IRT model, covariates were tested on the Base, Pmax,
and Drug parameters. Significant covariates (p < 0.001) on
Baseline in both models consisted of the baseline BII
score, baseline QoL score, and study region, while
baseline QoL score was included on PmaxIPSS
(Table IV). Due to the long runtime of the longitudinal
full ICC model, covariates were identified using the
longitudinal PSI-IPPSE approach and were subsequently
incorporated into the full longitudinal ICC model. Re-
estimation of the longitudinal parameters in the latter
yielded an OFV decrease of approximately 130 points,
and substantially better fit was observed in the VPCs of
the item-level and summary-level IPSS (data not shown).
Simultaneous re-estimation of ICCs and longitudinal
parameters (estimates shown in Supplemental Table S2)
yielded an OFV decrease of 11 points compared with the
fixed ICC longitudinal unidimensional IRT model. This
was deemed insignificant, and hence, the longitudinal
unidimensional IRT model with fixed ICCs and estimated
longitudinal parameters was kept as the final model. In
the latter, covariate relationships found to be significant
using the PSI-IPPSE method underwent an additional
backward elimination step (< 0.001) to confirm their
significance. All covariates remained statistically significant
in the full model. Lastly, Box-Cox transformation of the
Baseline and Drift IIV distributions in both models
resulted in significant drops in OFV. However, in longitu-
dinal unidimensional IRT modeling, the Box-Cox shape
parameter had a high relative standard error (> 400%)
and was therefore ultimately not included as part of the
final model.
During longitudinal bidimensional IRT modeling, high
correlation (≥ 96%) was observed between the Tprog IIV
and Pmax IIV components for each dimension, which
affected model stability. These IIV parameters were hence
collapsed into a single common parameter across the two
dimensions. The typical value of the Weibull exponent was
also estimated to be the same in both dimensions due to
model stability. As per the unidimensional IRT model,
longitudinal parameters were re-estimated in the final longi-
tudinal bidimensional IRT model. The final model minimized
successfully and its parameter estimates are shown in Table V.
It was not possible to obtain parameter precision estimates,
include covariates, or simultaneously estimate ICCs and
longitudinal parameters due to convergence and stability
issues. The final bidimensional longitudinal IRT model
adequately described both summary and item level data
(Supplemental Figs. S12 and S13, respectively).
Fig. 2. Item characteristic curves for each International Prostate Symptom Score item in the unidimensional item response
theory model
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Fig. 3. The International Prostate Symptom Score (IPSS) item characteristic curve fits in the unidimensional item response
theory model for the cumulative probabilities (red lines) along with cross-validated cubic spline generalized additive model
(GAM) smooth (green area) and η sampling-based cross-validated cubic spline GAM smooth using 200 samples (blue area)
Fig. 4. a Observed International Prostate Symptom Scores (IPSS) vs. item response theory disability estimates from the
unidimensional item response theory model based on 3117 separate measurements from 403 patients over the 6-month trial
period. b Observed change from baseline in International Prostate Symptom Scores (IPSS) vs. change from the baseline of
item response theory disability from the unidimensional item response theory model in 403 patients over the 6-month trial
period. MDD minimally detectable difference
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Power of Testing and Model-Based Methods
The bidimensional IRT model was used as the
simulation model in the SSE procedure as it provided a
lower AIC value (59,086.3) compared with the unidimen-
sional IRT model (AIC value of 61,622.6). The resulting
power curves are shown in Fig. 5. The pharmacometric
models all provided considerably higher power to detect a
drug effect compared with the cross-sectional ANCOVA
as well as the WOT ANCOVA. The unidimensional IRT
model yielded slightly higher power (approximately N =
113 to reach 80% power) compared with the total IPSS
model (approximately N = 120 to reach 80% power). An
additional SSE procedure confirmed this finding, using the
unidimensional IRT model as simulation model (data not
shown). The bidimensional IRT model provided the
highest power to detect a drug effect, allowing for a total
trial sample of approximately N = 106 to reach 80% power
compared with the total IPSS and unidimensional IRT
models. The type 1 error of each model under each
sample size and empirically derived OFV cut-off in the
SSE procedure is presented in the Supplemental Table S3.
Only model runs that minimized successfully were used in
the calculation of power (on average ~ 80% of full-
reduced bidimensional model pairs and ~ 90% of unidi-
mensional and total IPSS model pairs, respectively).
Table III. Fisher Information Content Ranking of International Prostate Symptom Score (IPSS) Items Based on the Unidimensional Item
Response Theory Model
IPSS item Item subscore category % of total Fisher information Cumulative % total
Q1: Incomplete Emptying Voiding 23.8 23.8
Q3: Intermittency Voiding 20.8 44.6
Q5: Weak Stream Voiding 15.4 60
Q2: Frequency Storage 13.1 73.1
Q6: Straining Voiding 11.8 84.9
Q4: Urgency Storage 11.6 96.5
Q7: Nocturia Storage 3.4 99.9
Table IV. Longitudinal model parameter estimates. IPSS: summary International Prostate Symptom Score, IRT: Item response theory.
Relative standard errors were obtained in NONMEM
IPSS model Unidimensional IRT model
Parameter Value Relative standard error (%) Value Relative standard error (%)
Baseline 19.6 1.7 0.0283 146.3
Pmax (maximal placebo response) − 4.12 9.9 − 1.03 10.9
Tprog (placebo half-life) 15.3 18.8 12.3 20.5
Drug effect − 1.98 19.2 − 0.542 20.3
Baseline Box-Cox shape 1.87 41.7 0.373 25.4
Drift Box-Cox shape 39.3 47.6 - -
Covariates
Baseline QoL on Pmax 0.208 13.2 - -
Baseline BII on Baseline 0.0211 19.6 0.121 17.9
Baseline QoL on Baseline 0.0873 12.7 0.325 17.4
Region on Baseline − 0.0803 26 − 0.338 24.1
Interindividual variability (IIV)
IIV Baseline 13.7% 8.3 75.9% 7.7
IIV Pmax 121.7% 15.4 128.5% 15.4
IIV Drift 1.8% 19.4 0.7% 8.8
IIV Tprog 90.6% 12 52.4% 9.9
IIV Baseline-Pmax correlation - - 1.7%
IIV Baseline-Drift correlation - - 9.2%
IIV Pmax-Drift correlation 43.1% 34%
Residual error
Proportional residual error 10.9% 8.9
Additive residual error 189.2% 6.7
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DISCUSSION
Item Response Theory Analysis
The current paper presents the first reported IRTanalyses of
the IPSS and longitudinal pharmacometric IRT model within
BPH-LUTS. Both a unidimensional and a bidimensional IPSS
IRT model were developed based on factor analyses, the latter
further confirming previous findings (41,42).
In the unidimensional IRT model, the vast majority of
the total information content was contained in IPSS voiding
items and this finding is supported by a principal component
analysis showing total IPSS being predicted by improvement
in voiding symptoms rather than storage symptoms (43).
Subscore analysis, i.e., distinguishing treatment effects on the
IPSS voiding and storage subscores in addition to the total
IPSS, is routinely performed as a secondary statistical analysis
of clinical trials within BPH-LUTS, although its clinical
meaningfulness has not been established (42,44,45). The
current results suggest that the IPSS voiding subscore is more
sensitive in assessing a patient’s BPH-LUTS in comparison
with the storage subscore and may therefore also be better
suited for detecting symptomatic drug effects. It is however to
be noted that the most favorable signal-to-noise ratio will be
obtained by regarding all available data and acknowledging
the information contribution of individual items as opposed
to considering the composite (sub)score(s), as exampled by
pharmacometric IRT in Parkinson’s disease (15).
Table V. Parameter estimates for the longitudinal bidimensional item
response theory model
Parameter Value
BaselineV (voiding scale) − 0.0251
BaselineS (storage scale) − 0.0667
PmaxV (maximal placebo response voiding scale) − 0.75
PmaxS (maximal placebo response storage scale) − 0.845
TprogV (placebo half-life voiding scale) 12.9
TprogS (placebo half-life storage scale) 13.4
Weibull shape parameter (common for both scales) 1.53
Drug effect voiding scale − 0.488
Drug effect storage scale − 0.749
Interindividual variability (IIV)
IIV Baselinev (voiding scale) 97.3%
IIV BaselineS (storage scale) 128.8%
IIV Baselinev-BaselineS correlation 26%
IIV Pmax (common for both scales) 145.6%
IIV Tprog (common for both scales) 61.1%
IIV Drift (common for both scales) 0.6%
IIV Pmax-Drift correlation 40%
Fig. 5. Power curves for the pharmacometric models obtained using a type I error corrected stochastic simulation and
estimation procedure. One thousand simulated data sets from the bidimensional item response theory model at sample sizes
of 33, 66, 99, and 137 patients were used for model estimation with the respective full (with a drug effect parameter) and
reduced (without a drug effect parameter) models. Vertical lines indicate the 95% confidence interval for the calculated
power estimates
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The incomplete emptying item was found to be the most
informative. This item has previously been found to be associated
with worsening of both voiding and storage symptoms (46).
Incomplete emptying had the highest discrimination parameter
value (1.38) in the unidimensional IRT model; however, com-
pared with other reported unidimensional IRT analyses in
different therapeutic areas, this is relatively low (e.g., the highest
discrimination parameter value was 3.35 in the ADAS-cog IRT
analysis (9) and 3.5 in the EDSS IRT analysis (12)). This may
indicate that BPH-LUTS is a diffuse and heterogeneous disease,
and consequently, IPSS items have difficulty in discriminating
between different levels of disability.
The nocturia item was found to be the least informative, and
several reports in the literature support this. Firstly, the item may
not be sufficiently specific to BPH-LUTS; the primary cause of
adult nocturnal polyuria has been attributed to the decline in
nocturnal secretion of antidiuretic hormone due to aging (47,48)
as opposed to being a direct consequence of BPH. The nocturia
item was also the least specific in Japanese men with BPH and a
similar explanation was proposed (49). Secondly, nocturia may be
unspecific to urologic conditions in general. Significant correlation
between IPSS nocturia and items 5 and 6 describing nocturia in
the 8-item overactive bladder questionnaire (OAB-8) has been
established (50); an IRT analysis of the OAB-8 in both men and
women showed the two items describing nocturia to have the
relatively lowest discrimination parameter values (51) (ratio to
the highest discrimination parameter estimate was 0.35, 0.40, and
0.42 for IPSS nocturia, OAB-8 item 5, and OAB-8 item 6,
respectively). It should be emphasized that nocturia and urgency
symptoms appear to be the most bothersome symptoms to
patients suffering fromLUTS (52,53). Lower information content
does not entail that the corresponding symptom is not bother-
some from a patient perspective; it indicates that the frequency of
observed scores varies less across patients with highly different
disease severity compared with other items. The item is therefore
less sensitive in assessing the overall condition and less useful for
distinguishing between patients. The bother of each BPH-LUTS
symptom is expected to vary between patients, yet this is not
captured by the IPSS; this diagnostic limitation (54) is addressed
by other questionnaires, e.g., theDanish Prostate Symptom Score
(55) and the International Continence Society Questionnaire
Male LUTS questionnaire (56).
Based on comparison between IRT disability and total IPSS,
the MDD of IPSS ≤− 3 for classifying patients as experiencing
clinically significant improvement (36,37) and IPSS≥ 4 for
determining clinical progression of BPH-LUTS (37–40) is
supported. However, seeing that there is extensive overlap
between changes in latent disability at the observed MDD and
below it (decreases lower than three total IPSS points and to a
certain extent increases in total IPSS), using only the change in
total IPSS to evaluate response may overlook many patients that
benefit from treatment. The same reasoning applies to patients
that experience worsening of their symptoms.
Discussion regarding the developed sampling-based
GAM smooth methodology for evaluating ICCs is presented
in the Supplemental Discussion.
Longitudinal Modeling
In both the longitudinal total IPSS and IRT models, a model
describing treatment as present or absent best described treatment
effect although three different drug doses (10 mg, 20 mg, and
30 mg) were included in the analyzed trial. Lack of observed dose-
response and exposure-response relationshipsmay be explained by
the narrow dose range studied in the current trial. Including at least
four active doses spanning an at least 10-fold range has previously
been emphasized to characterize dose-exposure-response ade-
quately (57). In the current trial, the width of the dose range was
restricted due to the expectation of an increase in the incidence of
prolonged testosterone suppression at higher doses of degarelix.
Further discussion regarding longitudinal modeling and covariate
analysis results are presented in the Supplemental Discussion.
The longitudinal bidimensional IRT model allowed for
estimation of a differential drug effect on voiding and storage
IPSS symptoms, while preserving item-level information. This
approach may be more in line with the different effects of
therapy on the primary pathophysiologies behind voiding and
storage symptoms (58,59). Limitations of the pharmacometric
bidimensional model included lack of longitudinal parameter
precision estimates and inability to include covariates. This
can be attributed to the increased model complexity due to
presence of several latent variables, and other longitudinal
pharmacometric multidimensional IRT models have reported
similar issues (13,14). More advanced and computationally
intensive methods for assessing parameter uncertainty (e.g., a
non-parametric bootstrap) may be used to obtain parameter
precision, but were beyond the scope of the current work.
Item- and summary-level VPCs were therefore the primary
basis for concluding adequate model fit and predictive
performance. If longitudinal model stability and covariate
identification are of primary interest, the longitudinal unidi-
mensional IRT model may be a better-suited alternative. The
unidimensional approach may also be advantageous for more
straightforward translation between changes in the summary
IPSS and IRT-estimated disability. From a psychometric
standpoint, both the unidimensional and bidimensional IPSS
IRT approaches are valid (41).
Power
The longitudinal model-based analyses showed consid-
erably higher power to detect a drug effect compared with the
cross-sectional ANCOVA using only data from the visit
3 months post-dose. The higher power of longitudinal
pharmacometric modeling compared with cross-sectional
testing is not a novel finding and has previously been reported
in several other therapeutic areas (9–11), yet comparison with
a WOT estimand-based test has to our knowledge not been
presented previously. These findings are discussed further in
the Supplemental Discussion.
A modest increase in power to detect a drug effect was
observedby the useof the unidimensional IRTmodeling compared
with the total IPSS model, and this finding was unexpected given
that other longitudinal IRT applications have shown greater
increases in power compared with longitudinal summary score
modeling (9,15). Studies have shown that the larger the number of
items in a questionnaire, the higher the power of IRT (60,61), and
this may explain the similar power between the summary IPSS
model and the unidimensional IRT model in the current study
compared with analyses of questionnaires with a higher number of
items. Furthermore, the heterogeneity in the item discrimination
parameter values has been shown to affect the power of IRT
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compared with summary score modeling (62). For instance, for the
8-item Expanded Disability Status Scale (EDSS) in multiple
sclerosis, pharmacometric IRT analysis showed a larger power
increase compared with summary score modeling (63) than in the
current study, which may be explained by the higher variability
between discrimination parameter estimates of EDSS items (66%
CV) compared with IPSS items (29% CV) (12). In the current
work, the bidimensional pharmacometric IRT model was used for
simulation of data on which the power to detect a drug effect was
estimated for the unidimensional IRT and total IPSS models,
respectively. A sensitivity analysis specifying the unidimensional
IRT model as the simulation model was performed and confirmed
the currently reported power difference between the
pharmacometric unidimensional IRT model and the total IPSS
model (data not shown).
A higher power to detect a drug effect was observed with the
longitudinal bidimensional IRT model compared with the unidi-
mensional IRT model. This may be due to the differences in ICCs
and disability scale of the multidimensional model compared with
the unidimensional model, which, in turn, give a more precise
discernment of the drug effect. Given a questionnaire where
multidimensionality is substantiated, we hypothesize that the
difference in power to detect a drug effect may increase compared
with a unidimensional IRTmodel as the correlation between latent
variables decreases, as this would gradually increase the difference
in ICCs and disability scale. This is the first investigation of the
impact of IRT dimensionality on the power to detect a drug effect
and hence warrants further investigation. For example, the original
application of pharmacometric IRT based on the ADAS-cog scale
(9) investigated the power of a unidimensional IRT model; based
onfindings suggesting that theADAS-cog ismultidimensional (64),
it may also be of interest to assess the power of a multidimensional
pharmacometric ADAS-cog IRT model.
A limitation of the current aswell as previous pharmacometric
IRTstudies (9,15,63) was that simulationmodel bias was present in
the power calculations: the pharmacometric IRT model used for
simulation of data was also used to estimate power and may
therefore have favored the pharmacometric IRT approaches.
Other approaches, such as developing longitudinal ordered
categorical models for each item and simulating data from these,
were considered. However, it is not clear whether the IPSS ICCs
would be preserved or require re-estimation based on simulated
data by doing so and whether meaningful comparison with
previously reported reductions in sample size would be feasible.
The current findings may serve to more precisely assess
patients’ underlying BPH-LUTS by utilizing the available
item-level IPSS responses instead of considering only the sum
of these scores. Furthermore, they may inform more efficient
clinical development of BPH-LUTS treatments, although the
gain in power to detect a drug effect was found to be lower
compared with previously reported applications with different
scales describing different neurological conditions (9,15,63).
IRT focuses on quantifying the information of questionnaires
in specific patient populations; since the modeled data
spanned the entire range of total IPSS (i.e., from the lowest
to the highest possible disease severity), the presented results
may be extended to the analysis of the IPSS in other clinical
trials including similar patients with moderate-to-severe BPH-
LUTS, regardless of treatment and its effect size.
5The current study emphasizes the importance of quantify-
ing the increase in power to detect a drug effect with
pharmacometric IRT modeling when applied to different mea-
surement scales, as it may differ to a great extent depending on
the internal characteristics of the latter. Knowledge regarding the
size of the increase in the power to detect a drug effect may be
primordial in informing a drug developer’s decision to implement
themore complex IRTmethodology. For completeness, it is to be
noted that pharmacometric modeling of longitudinal data is not
the current standard for detecting drug effects in clinical trials.
Further research regarding, e.g., its general alignment with
traditional statistical analyses, the adequacy of its underlying
assumptions, its type I error control, and its pre-specification (65–
67), is needed before it may be regarded as the primary analysis
method and thereby dictate the sample size of clinical trials.
The IRT methodology may be implemented in all clinical
trials where composite scores are used to assess treatment
efficacy, i.e., from proof-of-concept phase II to confirmatory
phase III trials. However, the shift from using “observed total
score” to “underlying disease” as the estimand summary
measure (32) may represent a substantial paradigm shift and
may therefore require framework developments supervised by
regulators. An example could be the development of standard-
ized item banks based on a large number of item-level patient
responses frommany trials. This would inform precise ICCs and
thereby allow for precise and, most importantly, consistent
estimation of latent disability across different clinical trials. The
merit and practical utility of IRT in increasing the efficiency of
clinical development programs appear to already be recognized
within the US Food and Drug Administration (68).
CONCLUSION
Pharmacometric models were developed based on item-
level and summary-level IPSS, respectively, to describe the
time course of underlying disability and total IPSS in patients
with moderate-to-severe BPH-LUTS in a clinical trial setting.
IRT analysis revealed that voiding IPSS items combined
contained the majority of the information content, which may
have implications for the analysis of IPSS subscores. The
unidimensional IRT model showed slightly higher power to
detect a drug effect compared with the composite score
model, while the bidimensional IRT model further increased
the power. Taking the multidimensional nature of the IPSS
into account in a pharmacometric IRT framework may hence
allow for more precise quantification of drug effects and
optimization of statistical power.
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